Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in New York, New York.
| Revenue (TTM) | $25.52M |
| Gross Profit (TTM) | $-10.18M |
| EBITDA | $-80.79M |
| Operating Margin | -120.00% |
| Return on Equity | -43.10% |
| Return on Assets | -24.50% |
| Revenue/Share (TTM) | $0.46 |
| Book Value | $2.24 |
| Price-to-Book | 2.47 |
| Price-to-Sales (TTM) | 10.42 |
| EV/Revenue | 7.42 |
| EV/EBITDA | 3.82 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 2745.00% |
| Shares Outstanding | $57.18M |
| Float | $36.85M |
| % Insiders | 10.96% |
| % Institutions | 74.90% |
Volatility is currently expanding
CLEVELAND, Ohio, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO).
Abeona Therapeutics NASDAQ: ABEO executives outlined the early commercial rollout of ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the Morgan Stanley Global Healthcare Conference. Management emphasized that the launch requires a longer foundation-building period than a conventional drug because of the therapy's individualized manufacturing process, limited shelf life and specialized treatment-center requirements.
- FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona's foundational R&D and clinical development efforts -
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO).
Abeona Therapeutics Inc. (ABEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced the activation of University of Florida Health (UF Health) in Gainesville, Florida, as the eighth Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN is the first and only autologous gene-modified cellular sheets for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO).
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO).
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ABEO and any ticker you trade — then tracks every position and per-strategy win rate.
